SCYNEXIS Inc (SCYX)

NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-10-23

$3.79-0.52%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge SCYNEXIS Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	135,500
EPS	—	-0.675
Annual ending 2026-12-31
Revenue	—	619,500
EPS	—	-2.91
Annual ending 2027-12-31
Revenue	—	1.31M
EPS	—	-2.315

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Achieve up to $146M in BREXAFEMME sales milestones	It targets up to $146 million in sales milestones for BREXAFEMME.	Intact	sales milestones fall significantly short of $146 million by 2029	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-FY guidance. The company disclosed potential milestone payments up to $146 million from BREXAFEMME sales by 2029. This remains a future revenue opportunity tied to the antifungal platform commercialization. Delivery assessment Oct 24, 2026
Maintain funding to support operations into mid-2029	The company secured funding to support operations into mid-2029.	Improving	funding falls short of sustaining operations through mid-2029	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Complete integration of Poxel's AMP kinase activator assets	SCYNEXIS is integrating Poxel's research assets to expand its drug pipeline.	Intact	integration progress stalls or reverses within next 12 months	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 2
2026-07-25	Unavailable	Unavailable	1 / 2
2026-07-26	Unavailable	Unavailable	1 / 2
2026-07-27	Unavailable	Unavailable	1 / 2
2026-07-28	Unavailable	Unavailable	1 / 2
2026-07-29	Unavailable	Unavailable	2 / 3
2026-07-30	Unavailable	Unavailable	1 / 2
2026-07-31	Unavailable	Unavailable	2 / 3
2026-08-01	Unavailable	Unavailable	1 / 2
2026-08-02	Unavailable	Unavailable	2 / 3
2026-08-03	Unavailable	Unavailable	1 / 2
2026-08-04	Unavailable	Unavailable	2 / 3
2026-08-05	Unavailable	Unavailable	1 / 2
2026-08-06	Unavailable	Unavailable	1 / 2
2026-08-08	Unavailable	Unavailable	2 / 3
2026-08-09	Unavailable	Unavailable	1 / 2
2026-08-10	Unavailable	Unavailable	2 / 3
2026-08-12	Unavailable	Unavailable	1 / 2
2026-08-13	Unavailable	Unavailable	2 / 3
2026-08-14	Unavailable	Unavailable	1 / 2
2026-08-15	Unavailable	Unavailable	1 / 2
2026-08-16	Unavailable	Unavailable	1 / 2
2026-08-17	Unavailable	Unavailable	1 / 2
2026-08-18	Unavailable	Unavailable	1 / 2
2026-08-19	Unavailable	Unavailable	1 / 2
2026-08-20	Unavailable	Unavailable	1 / 2
2026-08-21	Unavailable	Unavailable	1 / 2
2026-08-22	Unavailable	Unavailable	1 / 2
2026-08-23	Unavailable	Unavailable	1 / 2
2026-08-24	Unavailable	Unavailable	1 / 2
2026-08-25	Unavailable	Unavailable	1 / 2
2026-08-26	Unavailable	Unavailable	1 / 2
2026-08-27	Unavailable	Unavailable	1 / 2
2026-08-28	Unavailable	Unavailable	1 / 2
2026-08-29	Unavailable	Unavailable	1 / 2
2026-08-30	Unavailable	Unavailable	1 / 2
2026-08-31	Unavailable	Unavailable	1 / 2
2026-09-01	Unavailable	Unavailable	1 / 2
2026-09-02	Unavailable	Unavailable	1 / 2
2026-09-03	Unavailable	Unavailable	1 / 2
2026-09-04	Unavailable	Unavailable	1 / 2
2026-09-05	Unavailable	Unavailable	1 / 2
2026-09-06	Unavailable	Unavailable	1 / 2
2026-09-07	Unavailable	Unavailable	1 / 2
2026-09-08	Unavailable	Unavailable	1 / 2
2026-09-09	Unavailable	Unavailable	1 / 2
2026-09-10	Unavailable	Unavailable	1 / 2
2026-09-11	Unavailable	Unavailable	1 / 2
2026-09-12	Unavailable	Unavailable	1 / 2
2026-09-13	Unavailable	Unavailable	1 / 2
2026-09-14	Unavailable	Unavailable	1 / 2
2026-09-15	Unavailable	Unavailable	1 / 2
2026-09-16	Unavailable	Unavailable	1 / 2
2026-09-17	Unavailable	Unavailable	1 / 2
2026-09-18	Unavailable	Unavailable	1 / 2
2026-09-19	Unavailable	Unavailable	1 / 2
2026-09-20	Unavailable	Unavailable	1 / 2
2026-09-21	Unavailable	Unavailable	1 / 2
2026-09-22	Unavailable	Unavailable	1 / 2
2026-09-23	Unavailable	Unavailable	1 / 2
2026-09-24	Unavailable	Unavailable	1 / 2
2026-09-25	Unavailable	Unavailable	1 / 2
2026-09-26	Unavailable	Unavailable	1 / 2
2026-09-27	Unavailable	Unavailable	1 / 2
2026-09-28	Unavailable	Unavailable	1 / 2
2026-09-29	Unavailable	Unavailable	1 / 2
2026-09-30	Unavailable	Unavailable	1 / 2
2026-10-01	Unavailable	Unavailable	1 / 2
2026-10-02	Unavailable	Unavailable	1 / 2
2026-10-03	Unavailable	Unavailable	1 / 2
2026-10-04	Unavailable	Unavailable	1 / 2
2026-10-05	Unavailable	Unavailable	1 / 2
2026-10-06	Unavailable	Unavailable	1 / 2
2026-10-07	Unavailable	Unavailable	1 / 2
2026-10-08	Unavailable	Unavailable	1 / 2
2026-10-09	Unavailable	Unavailable	1 / 2
2026-10-10	Unavailable	Unavailable	1 / 2
2026-10-11	Unavailable	Unavailable	1 / 2
2026-10-12	Unavailable	Unavailable	1 / 2
2026-10-13	Unavailable	Unavailable	1 / 2
2026-10-14	Unavailable	Unavailable	1 / 2
2026-10-15	Unavailable	Unavailable	1 / 2
2026-10-16	Unavailable	Unavailable	1 / 2
2026-10-17	Unavailable	Unavailable	1 / 2
2026-10-18	Unavailable	Unavailable	1 / 2
2026-10-19	Unavailable	Unavailable	1 / 2
2026-10-20	Unavailable	Unavailable	1 / 2
2026-10-21	Unavailable	Unavailable	1 / 2
2026-10-22	Unavailable	Unavailable	1 / 2
2026-10-23	Unavailable	Unavailable	1 / 2
2026-10-24	Unavailable	Unavailable	1 / 2

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	3	0	0
2026-06-01	3	0	0
2026-07-01	3	0	0
2026-08-01	3	0	0
2026-09-01	3	0	0
2026-10-01	3	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Achieve up to $146M in BREXAFEMME sales milestonesDirect metric needs a verified mapping
Maintain funding to support operations into mid-2029Direct metric needs a verified mapping
Complete integration of Poxel's AMP kinase activator assetsDirect metric needs a verified mapping

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.7%Typical daily move · historical

Downside history

-35.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

SCYNEXIS Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

SCYX is a high-risk, loss-making clinical-stage biotech with commercial and development programs. Its long-term thesis is intact, supported by new funding for SCY-247, but evidence on execution is mixed and confidence is medium.

What's priced into SCYNEXIS Inc

The valuation evidence describes SCYX as cheap versus peers, with expectations somewhat below the model’s baseline. The priced-in assessment is tagged justified, and no fragility gates fired, though the evidence does not specify which operating assumptions the market already expects.

What the fundamentals likely do

Near term, erratic earnings surprises and smaller-company risk make the next report worth watching, and a guidance cut is a stated negative scenario. Over the multi-year view, BARDA funding supports SCY-247 development, while SCY-770 remains in development with cash runway stated into 2029; BREXAFEMME milestone payments remain a future opportunity rather than achieved revenue.

What SCYNEXIS Inc hinges on

The thesis hinges on advancing SCY-247 through its planned development stages and making progress on SCY-770, alongside any BREXAFEMME sales milestones. Near-term risks include weaker guidance, worsening economic signals, litigation, and the recently higher risk label; supportive healthcare-sector results could help the sector backdrop.